Charts

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock. This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The Company enacted a similar program in June 2022.

Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, announces today that its Board of Directors has empowered its Business Review Committee to evalu

PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to Iroquois Capital’s filing of a preliminary consent statement to commence a consent solicitation in lieu of a stockholder meeting. Iroquois Capital is seeking the consent of the Company’s shareholders to change various Company Bylaws, expand the size of the Company’s Board of Directors (Board) from 7 to 15, and elect Iroquois’ entire slate of 8 directors to the Board. The Company has serious concerns with this recent action taken by Iroquois and portends trouble ahead for the Company and its shareholders.

Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB), with an aggregate ownership stake together with the other participants in its solicitation of approximately 7.2% of the Company's outstanding shares, today announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a sto

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte has complied with related to the requests from the U.S. Food and Drug Administration (FDA) to lift the clinical hold on PharmaCyte’s planned Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer (LAPC).

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypsCaps™ plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascites.

Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.

Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ: PMCB) seeking the consent of stockholders to expand the size of PharmaCyte's Board of Directors by eight (8) members and to elect Iroquois' slate of eight (8) highly qualified director candidates in lieu of a stockholder meeting. Iroquois also announced that it has

Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.3% of the outstanding common stock of the Company, today provided the following statement in response to certain actions recently taken by the Company, which Iroquois believes are a thinly-veiled attempt to entrench the incumbent directors on the Company's Board o

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of a study to determine whether a previous established quantitative real-time PCR (qRT-PCR) could be used as a quality control test for its CypCaps™ product candidate. The qRT-PCR was used to gain data from testing of syringes from clinical batches of PharmaCyte’s cGMP production for its planned clinical trial in locally advanced, inoperable pancreatic cancer.

Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.1% of the outstanding common stock of the Company, today announced that it has nominated a slate of seven (7) highly qualified director candidates for election to the PharmaCyte Board of Directors at the Company's upcoming 2022 annual meeting of stockholders. Iroquois als

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022:

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO) being held at the San Diego Convention Center in San Diego, California, June 13-16.

Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 5.8% of the outstanding common stock of the Company, today announced that it has delivered a letter to the Company's Board of Directors.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following letter to its shareholders in response to the concerns expressed by Iroquois Capital Management (Iroquois) in its letter to the PharmaCyte Board of Directors (Board) dated May 11, 2022, and announces additional steps to increase shareholder value:

PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites. The initiation of this first study was made possible after PharmaCyte’s successful production of a Master Cell Bank as well as the demonstration that the Master Cell Bank is adventitious agent free.

PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The ...

Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market ...

PharmaCyte Biotech announces another positive test result. The result shows that CypCap material does not cause systemic toxicity.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Löhr to PharmaCyte’s Board of Directors.

PharmaCyte Biotech successfully completed a 24-month stability study of its clinical trial product candidate.

PharmaCyte Biotech reports positive third quarter results and operational highlights.

PharmaCyte announces genetic stability of the cytochrome P450 gene and site of integration for its pancreatic cancer product candidate.

PharmaCyte Biotech Inc(NASDAQ: PMCB)updated its activities to lift the FDA's clinical holdon PharmaCyte's ...

PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA.

Gainers Epizyme (NASDAQ:EPZM) shares increased by 7.3% to $1.32 during Tuesday's after-market session. Epizyme's trading volume hit ...

PharmaCyte Biotech Chief Executive Officer to present at the H.C. Wainwright BioConnect Conference.

PharmaCyte Biotech biocompatibility study proves that its capsule material is not toxic for the encapsulated cells inside the capsules.

PharmaCyte has successfully completed a 36 month stability study on its Master Cell Bank cells that will be used for treatment of pancreatic cancer.

PharmaCyte Biotech reports on its second quarter financial results and its operational highlights.

PharmaCyte Biotech successfully complete the cytochrome P450 site of integration DNA sequencing assay required by the FDA to lift the clinical hold.

PharmaCyte Biotech launches its malignant ascites program with commencement of a pivotal preclinical study.

PharmaCyte Biotech announces that its clinical trial product material does not cause skin irritation passing another biocompatibility test.

Upgrades For Nektar Therapeutics (NASDAQ:NKTR), Benchmark upgraded the previous rating of Hold to Buy. Nektar ...

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an ...

Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market ...

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

PharmaCyte Biotech announces that its encapsulation material does not alter cellular DNA.

PharmaCyte Biotech releases more positive results from the FDA required biocompatibility tests. The clinical trial capsules passed the tests.

PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of ...

PharmaCyte Biotech announces positive results of one of the biocompatibility studies required by the FDA.

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence. The post After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

The stock price ofPharmaCyte Biotech Inc(NASDAQ: PMCB) is trading higher during premarket today. Investors are ...

Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We're starting off the day with a dive into the biggest pre-market stock movers for Thursday as shares climb and fall. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

PharmaCyte Biotech participates in the H.C. Wainwright 23rd Annual Global Investment Conference.